Karyopharm Therapeutics Inc (KPTI) was Initiated by H.C. Wainwright to “Buy” and the brokerage firm has set the Price Target at $15. H.C. Wainwright advised their investors in a research report released on Aug 18, 2016.
Many Wall Street Analysts have commented on Karyopharm Therapeutics Inc. Robert W. Baird Initiated Karyopharm Therapeutics Inc on Jun 28, 2016 to “Outperform”, Price Target of the shares are set at $16.Raymond James Initiated Karyopharm Therapeutics Inc on May 27, 2016 to “Outperform”, Price Target of the shares are set at $13.
Karyopharm Therapeutics Inc closed down -0.21 points or -2.92% at $6.99 with 1,02,212 shares getting traded on Wednesday. Post opening the session at $7.21, the shares hit an intraday low of $6.9231 and an intraday high of $7.2717 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
In a different news, on Dec 10, 2015, Mansoor Raza Mirza (director) sold 15,000 shares at $15.01 per share price. According to the SEC, on Apr 8, 2015, Ran Frenkel (EVP, WW Development Operations) purchased 3,000 shares at $31.22 per share price. On Apr 6, 2015, Justin A Renz (CFO) purchased 5,000 shares at $29.71 per share price, according to the Form-4 filing with the securities and exchange commission.
Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other diseases. The Company is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibits the nuclear export protein XPO1. The Company is seeking the regulatory approval and commercialization of its lead drug candidate selinexor (KPT-330) as a single orally administered agent in cancer indications with unmet clinical need initially for hematologic malignancies. It is also advancing the clinical development of selinexor in multiple solid tumor indications. The Company has initiated three registration-directed trials in hematological cancers with selinexor and anticipates initiating a fourth registration-directed trial.